Christopher Feinmann  
Technology Appraisal Project Manager  
NICE  
Peter House, Manchester.

31 October 2006

Single Technology Appraisal (STA)  
Fludarabine monotherapy for the first line treatment of chronic lymphocytic leukaemia  
Appraisal Consultation Document

Dear Christopher

Thank you very much for inviting CHILDREN with LEUKAEMIA to comment on this STA.

I have consulted extensively with our medical colleagues at Great Ormond Street hospital who treat childhood leukaemia. Although they occasionally use Fludarabine for acute childhood leukaemia, they confirmed that children do not develop chronic lymphocytic leukaemia and therefore I do not feel it is appropriate or helpful for us to comment on this STA.

We would, however, be very interested in taking part in any future NICE consultation processes, particularly those relating to leukaemia in children.

Thank you.

CHILDREN with LEUKAEMIA